68Ga-NYM005 not checked
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “he radiation dose is about 2-7 mCi for a single patient.Using a syringe to withdraw 68Ga-NYM005 injection, the dose will be administered via an intravenous injection and the injection time will be about 45-60 seconds.”In the company’s words, NCT06389682 on ClinicalTrials.gov
- Main trialPhase 1/2
- “68Ga-NYM005 is a CAIX-targeting small-molecular radiotracer for PET/CT imaging of clear cell renal cell carcinoma”In the company’s words, NCT06389682 on ClinicalTrials.gov
Other drugs for Clear Cell Renal Cell Carcinoma Metastatic
- CasdatifanArcus Biosciences · Phase 3
- AB-2100Arsenal Biosciences, Inc. · Phase 1/2
- EB-701/CA9-NKBeijing Biotech · Phase 1/2
- AxitinibPfizer · Phase 1/2
- PF-08634404Pfizer · 3SBio · Phase 1/2
- NEO-811Neomorph, Inc · Phase 1
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Completed | 8 Jan 2025 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM005 in Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026